Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial
答案Answerball
5天前
57
10
已关闭
DOI: 10.1016/s2213-8587(25)00290-6
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S2213858725002906
其他信息:
出版社: Elsevier BV
作者: Frederick J Raal; Jean Bergeron; Daniel Gaudet; Robert S Rosenson; David R Sullivan; Traci Turner; Robert A Hegele; Christie M Ballantyne; Joshua W Knowles; Nicholas J Leeper; Ira J Goldberg; Rong Zhou; Ma'an Muhsin; Jennifer Hellawell; James Hamilton; Gerald F Watts
